Analysis
Setara Biosciences has launched with $90 million in Series A financing to carry forward a pipeline of precision medicines for rare genetic diseases that Jazz Pharmaceuticals left behind after its $820 million acquisition of Actio Biosciences, the spinout said.
What does Setara Biosciences do?
Setara is based in San Diego and is led by co-founder, President and Executive Chair David Goldstein, who was also chief executive of Actio, alongside co-founder and Chief Scientific Officer David Breckenridge, according to the company. Cayce Denton serves as chief financial officer and Pete Condon as chief business officer, rounding out an executive team drawn largely from Actio's existing leadership. Its lead program, STAR-0871, is an orally available small-molecule inhibitor of TRPV4 being developed for Charcot-Marie-Tooth disease type 2C and overactive bladder, with a Phase 1b study in CMT2C patients planned by the end of the year, BioPharma Dive reported. A second, earlier-stage program targets genetic epilepsy and other central-nervous-system disorders.
How much has Setara Biosciences raised?
Jazz Pharmaceuticals paid $820 million to acquire Actio Biosciences, and Setara's $90 million Series A was built specifically to carry the drug candidates Jazz didn't want into a standalone company, with Jazz itself taking a minority stake in the new entity, BioPharma Dive reported. This is Setara's first disclosed funding round, and the $90 million figure is notably larger than many single-asset biotech spinouts raise at launch -- a reflection of the fact that Setara inherited an already-advanced clinical program rather than starting from a discovery-stage platform.
“Named head-to-head competitors in TRPV4-targeted therapeutics were not available in the sources reviewed for this story.”
Who invested in Setara Biosciences?
Deerfield Management, Canaan, Droia Ventures, EcoR1 Capital, Euclidean Capital, Regeneron Ventures and Jazz Pharmaceuticals all backed the Series A, according to Setara's own investor list. "Many of Actio's early investors are bankrolling the new company, including Deerfield Management, Canaan and Jazz," BioPharma Dive reported, noting that no single investor was identified as lead.
Rare-disease drug market and competitors
Vertex Pharmaceuticals built a multibillion-dollar franchise by commercializing precision medicines for a genetically defined, historically underserved patient population -- the same playbook Setara is attempting with CMT2C, a rare peripheral-nerve disease, and with overactive bladder, which BioPharma Dive says affects tens of millions of people in the U.S. Named head-to-head competitors in TRPV4-targeted therapeutics were not available in the sources reviewed for this story.
Setara's entire pipeline sits ahead of Phase 1b, and the company has not disclosed a valuation for the round, leaving open how richly investors are actually pricing the Actio-derived assets versus simply preserving optionality on programs Jazz chose not to keep. Biotech spinouts built around assets a larger company declined to keep have become more common as pharma consolidates deal activity around its highest-conviction programs, giving venture investors a way to back de-risked clinical assets without funding early discovery work. Setara's structure, with Jazz retaining a minority stake rather than fully divesting, lets Jazz keep exposure to any future upside without carrying the ongoing trial costs itself.
What to watch next
The Phase 1b readout in CMT2C patients, expected by the end of 2026 per the company's own timeline, is the first real test of whether STAR-0871 can replicate Actio's original thesis outside Jazz's umbrella. Pulse tracks rare-disease and biotech financings on its funding tracker; Setara is a new addition to that list.